A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

• Status: WITHDRAWN
• Trial end date: 2030-09-21

Summary

The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).

• Phase: PHASE3

Details

• Lead Sponsor: Celgene
• Treatments: carfilzomib; daratumumab; Dexamethasone; elotuzumab; pomalidomide